NovelMed is an early stage biotechnology company that develops innovative therapies for patients who suffer from some of the most prevalent unmet medical conditions of our time. NovelMed’s scientists continuously research and develop cutting-edge treatments targeting diseases for which no cure currently exists. Our intellectual vigor and commitment to world-class research that dramatically improves patients’ lives has attracted a dedicated and creative multidisciplinary team of scientists that approaches the challenge of drug discovery from multiple therapeutic perspectives.

Guided by these skilled researchers, NovelMed’s technology platforms have already led to new small molecule and monoclonal antibody based therapeutics for the treatment of arthritis, cardiovascular disease, stroke, and cancer. These discoveries and our ongoing R&D efforts have put NovelMed at the cutting-edge of drug development.